应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
06990 科伦博泰生物
未开盘 10-20 16:08:20
468.000
+16.000
+3.54%
最高
473.000
最低
448.000
成交量
70.96万
今开
458.000
昨收
452.000
日振幅
5.53%
总市值
1,119亿
流通市值
828.36亿
总股本
2.39亿
成交额
3.31亿
换手率
0.40%
流通股本
1.77亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
创新药概念强势 翰森制药（03692）涨逾7% 前三季对外技术授权约1300亿美元接近25年全年
金吾财讯 · 10-20 11:23
创新药概念强势 翰森制药（03692）涨逾7% 前三季对外技术授权约1300亿美元接近25年全年
生物医药板块走强 康诺亚-B（02162）涨9.00%、金斯瑞生物科技（01548）涨7.53%
金吾财讯 · 10-16
生物医药板块走强 康诺亚-B（02162）涨9.00%、金斯瑞生物科技（01548）涨7.53%
异动解读｜科伦博泰生物盘中上涨4.47%，机构增持叠加板块走强
行情直击 · 10-16
异动解读｜科伦博泰生物盘中上涨4.47%，机构增持叠加板块走强
创新药概念走强 百济神州（06160）涨超4% 机构认为板块长期前景改善
金吾财讯 · 10-15
创新药概念走强 百济神州（06160）涨超4% 机构认为板块长期前景改善
小摩：中国生物科技ESMO催化剂可验证本土创新 首选科伦博泰生物及信达生物
新浪港股 · 10-14
小摩：中国生物科技ESMO催化剂可验证本土创新 首选科伦博泰生物及信达生物
汇添富基金管理股份有限公司增持科伦博泰生物(06990)6.2万股 每股作价约454.07港元
智通财经 · 10-13
汇添富基金管理股份有限公司增持科伦博泰生物(06990)6.2万股 每股作价约454.07港元
小摩：中国生物科技ESMO催化剂可验证本土创新 首选科伦博泰生物(06990.HK)信达生物(01801.HK)
智通财经 · 10-13
小摩：中国生物科技ESMO催化剂可验证本土创新 首选科伦博泰生物(06990.HK)信达生物(01801.HK)
科伦博泰生物：刘革新减持，好仓比例降至49.28%
港股披露 · 10-09
科伦博泰生物：刘革新减持，好仓比例降至49.28%
科伦博泰生物：刘革新减持，好仓比例降至49.32%
港股披露 · 10-09
科伦博泰生物：刘革新减持，好仓比例降至49.32%
小摩：不太担心利率上升影响中国医疗健康行业 继续看好生物科技及CXO
智通财经 · 10-06
小摩：不太担心利率上升影响中国医疗健康行业 继续看好生物科技及CXO
科伦博泰生物发布2026年9月股份变动月报表，股本维持稳定
公告速递 · 10-02
科伦博泰生物发布2026年9月股份变动月报表，股本维持稳定
异动解读｜科伦博泰生物盘中下跌3.45%，报461.6港元
行情直击 · 10-02
异动解读｜科伦博泰生物盘中下跌3.45%，报461.6港元
异动解读｜科伦博泰生物盘中上涨3.42%，芦康沙妥珠单抗多项研究入选ESMO大会LBA叠加板块共振
行情直击 · 09-30
异动解读｜科伦博泰生物盘中上涨3.42%，芦康沙妥珠单抗多项研究入选ESMO大会LBA叠加板块共振
东方证券股份有限公司(DFZQ)增持科伦博泰生物(06990.HK)2.52万股 每股作价约490.76港元
智通财经 · 09-29
东方证券股份有限公司(DFZQ)增持科伦博泰生物(06990.HK)2.52万股 每股作价约490.76港元
科伦博泰生物：东方证券增持，好仓比例升至5.0%
港股披露 · 09-29
科伦博泰生物：东方证券增持，好仓比例升至5.0%
创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%
金吾财讯 · 09-29
创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%
异动解读｜科伦博泰生物盘中上涨4.17%，芦康沙妥珠单抗多项研究入选ESMO大会LBA叠加板块共振
行情直击 · 09-29
异动解读｜科伦博泰生物盘中上涨4.17%，芦康沙妥珠单抗多项研究入选ESMO大会LBA叠加板块共振
汇添富基金管理股份有限公司增持科伦博泰(06990.HK)2.52万股 每股作价约490.76港元
智通财经 · 09-24
汇添富基金管理股份有限公司增持科伦博泰(06990.HK)2.52万股 每股作价约490.76港元
生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖
金吾财讯 · 09-24
生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖
花旗：医药工业发展“十五五”规划利好创新药及医疗器械 首选石药集团(01093)等
智通财经 · 09-21
花旗：医药工业发展“十五五”规划利好创新药及医疗器械 首选石药集团(01093)等
加载更多
公司概况
公司名称：
科伦博泰生物
所属市场：
SEHK
上市日期：
--
主营业务：
四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。
发行价格：
--
{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物","latestPrice":468,"timestamp":1792483700006,"preClose":452,"halted":0,"volume":709561,"delay":0,"changeRate":0.035398230088495575,"floatShares":177000000,"shares":239000000,"eps":-1.65683,"marketStatus":"未开盘","change":16,"latestTime":"10-20 16:08:20","open":458,"high":473,"low":448,"amount":330864080,"amplitude":0.05531,"askPrice":468,"askSize":2300,"bidPrice":466,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.748354,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792546200000},"marketStatusCode":0,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":452,"openAndCloseTimeList":[[1792459800000,1792468800000],[1792472400000,1792483200000]],"volumeRatio":1.216179,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"2676665575","title":"创新药概念强势 翰森制药（03692）涨逾7% 前三季对外技术授权约1300亿美元接近25年全年","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665575","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665575?lang=zh_cn&edition=full","pubTime":"2026-10-20 11:23","pubTimestamp":1792466598,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念强势，截至发稿，乐普生物 涨8.81%，翰森制药涨7.06%，药明生物涨6.74%，晶泰控股涨4.56%，康诺亚-B涨4.70%，亚盛医药涨4.30%，恒瑞医药涨4.16%，药明合联涨3.96%，云顶新耀涨3.89%，和黄医药涨3.68%，中国生物制药涨3.24%，石药集团涨3.16%，科伦博泰生物涨3.14%，诺诚健华涨3.08%。消息面上，据人民财讯，10月20日，国家发展改革委召开10月份新闻发布会，会上提到，我国前三季度创新药对外技术授权约1300亿美元，接近去年全年。","market":"sg","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993987","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518931.SGD","BK1576","06990","06978","02157","LU0128522744.USD","LU0359201885.HKD","LU0979878070.USD","LU0417516738.SGD","LU0052750758.USD","LU0211977185.USD","LU1152091754.HKD","KURE","02162","02228","LU0196878994.USD","LU1008478684.HKD","MEDX","IBBQ","02269","LU0417516902.SGD","06855","BK1589","LU0072913022.USD","LU1794554557.SGD","LU0043850808.USD","BK1161","159992","02268","LU1226288170.HKD","BK1521","LU2488822045.USD","LU2543165471.USD","01093","LU0348827113.USD","LU1993786604.SGD","LNGR","LU1188198961.HKD","03692","01952","01276","00013","01177","BK1610","LU1720050803.USD","IE0008369823.USD","LU2476274720.SGD","LU1242518857.USD","LU0588546209.SGD","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675542315","title":"生物医药板块走强 康诺亚-B（02162）涨9.00%、金斯瑞生物科技（01548）涨7.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675542315","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675542315?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:37","pubTimestamp":1792114658,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块走强，康诺亚-B 涨9.00%，金斯瑞生物科技涨7.53%，百济神州涨5.38%，科伦博泰生物涨5.25%，再鼎医药涨4.46%，君实生物涨3.71%，泰格医药涨3.65%，复宏汉霖涨2.99%。中信建投证券表示，2026 ESMO LBA中国研究入选创新高，恒瑞医药、康方生物、艾力斯等企业的管线迎来新进展。医药商业板块跑赢申万医药及大盘，药店关注三季度前瞻及集采进药店，流通关注回款及三季度前瞻。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993835","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK4588","LU1770034418.SGD","09688","BK1515","BK1576","06160","BK4581","BK4585","BK1587","KURE","LU0588546209.SGD","03347","161726","06990","LU2488822045.USD","HK0000165453.HKD","LU1251922891.USD","LU0228659784.USD","399441","LU0307460666.USD","LU1719994722.HKD","BK1583","HK0000320264.USD","LU2328871848.SGD","XBI","BK1141","LU0196878994.USD","BK1588","LU1303224171.USD","02696","BK1574","HK0000320223.HKD","BK1161","HK0000306685.HKD","01548","BK1500","01877","LU0828237510.HKD","HK0000306701.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172613247","title":"异动解读｜科伦博泰生物盘中上涨4.47%，机构增持叠加板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1172613247","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172613247?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:33","pubTimestamp":1792114423,"startTime":"0","endTime":"0","summary":"10月16日，科伦博泰生物盘中上涨4.47%，报462.8港元，成交额5288.05万港元。消息面上，10月13日披露权益变动显示，汇添富基金于10月8日场内增持6.2万股，均价约454.07港元，涉资约2815.21万港元，增持后持股升至886.01万股，持股比例达5.01%。同时，小摩近日指出，中国生物科技板块在ESMO会议上的催化剂有望验证本土创新，首选科伦博泰生物与信达生物。此前公司上半年实现营收9.78亿元、经调整净利润4.79亿元，商业化兑现亦提供基本面支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物获机构增持，股价盘中上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675037153","title":"创新药概念走强 百济神州（06160）涨超4% 机构认为板块长期前景改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2675037153","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675037153?lang=zh_cn&edition=full","pubTime":"2026-10-15 09:59","pubTimestamp":1792029581,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念走强，截至发稿，百济神州 涨4.11%，翰森制药涨3.14%，中国生物制药涨3.10%，再鼎医药涨2.80%，石药集团涨2.10%，科伦博泰生物涨2.06%。消息面上，里昂发表研究报告指，中国医疗保健板块处周期底部，管线进展有望提振情绪。中国创新资产为世界肺癌大会的重要亮点，料于欧洲肿瘤内科学会大会继续受关注；该行认为，目前各治疗领域的临床领先地位，将塑造未来市场份额。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1993745","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","SG9999004220.SGD","IE00BZ08YT58.USD","LU0828237510.HKD","LU0307460666.USD","LU1719994722.HKD","03692","BK4588","LU1960683339.HKD","BK1588","IE0008368742.USD","LU1008478684.HKD","01177","BK1521","LU0501845795.SGD","159992","BK1583","LU0228659784.USD","BK1589","LU1770034418.SGD","01093","06990","BK4585","688235","LU1993786604.SGD","LU0067412154.USD","LU2039709279.SGD","LU1303224171.USD","LU1251922891.USD","IE0008369823.USD","09688","LU0140636845.USD","BK1515","KURE","IBBQ","06978","LU0072913022.USD","LU1226288253.USD","LU0588546209.SGD","HK0000165453.HKD","BK4139","LU2328871848.SGD","LU0314109678.HKD","LU1813983027.USD","ONC","06160","BK0239","LNGR","LU1152091168.USD","LU1951186391.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675152853","title":"小摩：中国生物科技ESMO催化剂可验证本土创新 首选科伦博泰生物及信达生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2675152853","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675152853?lang=zh_cn&edition=full","pubTime":"2026-10-14 14:30","pubTimestamp":1791959400,"startTime":"0","endTime":"0","summary":"模拟交易客户端10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与项飙现场对话！该行覆盖的逾20只中国生物科技股上周下跌4.4%，跑输恒生指数升1.8%。ESMO论文摘要预计于10月18日美东时间晚上6时发布，海报预计于10月23日上线，ESMO会议于10月23至27日举行。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-10-14/doc-iniveqvs1150233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443465.HKD","LU0640476718.USD","LU0942090050.USD","LU1366192091.USD","LU0211327993.USD","LU0203345920.USD","LU0943347566.SGD","VFH","LU0157215616.USD","UYG","LU0868494708.USD","LU1267930490.SGD","LU0251132253.USD","BK1610","IYG","XLF","TRUF","LU0106261372.USD","LU0196878994.USD","LU0267386448.USD","LU1363072403.SGD","01801","LU1119994496.HKD","LU2505996509.AUD","JPMO","LU2552382132.HKD","BK4566","LU0211328371.USD","IE00BHPRN162.USD","06990","03069","IXG","FTXO","IE00BKDWB100.SGD","LU0211326839.USD","IE00BKVL7J92.USD","TFNS","LU2756315318.SGD","LU0787776722.HKD","FNCL","IE00B1BXHZ80.USD","JPO","KURE","LU2242644610.SGD","KBWB","LU0417517546.SGD","BK1589","LU2462157665.USD","IE00B775SV38.USD","IYF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675356387","title":"汇添富基金管理股份有限公司增持科伦博泰生物(06990)6.2万股 每股作价约454.07港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675356387","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675356387?lang=zh_cn&edition=full","pubTime":"2026-10-13 19:01","pubTimestamp":1791889307,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，10月8日，汇添富基金管理股份有限公司增持科伦博泰生物(06990)6.2万股，每股作价454.0655港元，总金额约为2815.21万港元。增持后最新持股数目为886.01万股，最新持股比例为5.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1506611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","EWH","BK1161","LU0196878994.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675311143","title":"小摩：中国生物科技ESMO催化剂可验证本土创新 首选科伦博泰生物(06990.HK)信达生物(01801.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675311143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675311143?lang=zh_cn&edition=full","pubTime":"2026-10-13 15:50","pubTimestamp":1791877833,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1969619763.USD","LU0149534421.HKD","LU2097828631.EUR","LU2097828805.USD","BK1610","LU2242644610.SGD","LU0455707207.USD","LU0244354667.USD","LU0607220059.USD","LU1188198961.HKD","LU2328871848.SGD","LU1831875114.USD","HK0000165453.HKD","LU0326950275.SGD","BK1589","LU0463099449.HKD","LU2097828474.EUR","LU2488822045.USD","BK1161","BK1583","LU0196878994.USD","KURE","01801","LU2097828557.USD","LU2097828714.EUR","03069","06990","LU0502904849.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194603397","title":"科伦博泰生物：刘革新减持，好仓比例降至49.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1194603397","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194603397?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:14","pubTimestamp":1791537253,"startTime":"0","endTime":"0","summary":"刘革新于2026年10月9日通过其控制的员工持股平台（科伦汇德、科伦汇能、科伦汇智、科伦汇才）在联交所场内以每股均价439.94港元减持科伦博泰生物股份6.60万股，涉资约2903.60万港元，属场内主动交易，即在二级市场直接买卖股份。刘革新此次减持前持有科伦博泰生物好仓8720.90万股，占比49.32%；减持后持股量为8714.30万股，好仓比例降至49.28%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172454073","title":"科伦博泰生物：刘革新减持，好仓比例降至49.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=1172454073","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172454073?lang=zh_cn&edition=full","pubTime":"2026-10-09 17:12","pubTimestamp":1791537173,"startTime":"0","endTime":"0","summary":"刘革新于2026年10月8日通过其控制的员工持股平台在联交所场内以每股均价456.05港元卖出科伦博泰生物（06990）5.26万股，涉资约2398.82万港元，属场内主动交易，即在二级市场直接买卖股份。刘革新此次减持前持有科伦博泰生物好仓8726.16万股，占比49.35%；减持后持股量为8720.90万股，好仓比例降至49.32%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673035134","title":"小摩：不太担心利率上升影响中国医疗健康行业 继续看好生物科技及CXO","url":"https://stock-news.laohu8.com/highlight/detail?id=2673035134","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673035134?lang=zh_cn&edition=full","pubTime":"2026-10-06 11:32","pubTimestamp":1791257520,"startTime":"0","endTime":"0","summary":"另外，该行预期本轮加息周期将于12月再加息一次后结束，而非延续至明年的长期紧缩，因此对利率上升影响中国医疗健康估值并不太担心，并继续看好生物科技及CXO子板块。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1503851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159837","JPMO","03696","TFNS","LNGR","01548","XBI","LABU","IYF","TRUF","SYNB","159760","WX","IXJ","02269","LU0345769128.USD","IEIH","FTXO","XLV","IE0034235295.USD","JPO","IXG","MEDX","02268","FNCL","06990","KURE","LU1670627923.USD","AGNG","KBWB","LU0976567544.SGD","HBImain","LU0345769631.USD","LU0708995153.HKD","XLF","LU1974910355.USD","02359","UYG","IBBJ","LU0572944931.SGD","IYG","XLBI","GDOC","PEX","VFH","EQRR","IE00BKDWB100.SGD","VHT","CXO","LU2168564065.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160120611","title":"科伦博泰生物发布2026年9月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1160120611","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160120611?lang=zh_cn&edition=full","pubTime":"2026-10-02 16:37","pubTimestamp":1790930224,"startTime":"0","endTime":"0","summary":"2026年10月2日，四川科伦博泰生物医药股份有限公司发布截至2026年9月30日的股份变动月报表。公告日期为2026年10月2日，报告期覆盖2026年9月。本次公告显示，科伦博泰生物于报告期末的法定/注册股本总额为人民币239,023,969元，其中H股为176,822,257股，内资股为62,201,712股。与上月底相比，上述股本数量和结构均无增减变动，保持不变。本次月度股份变动报告由公司秘书周泽剑签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109307705","title":"异动解读｜科伦博泰生物盘中下跌3.45%，报461.6港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109307705","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109307705?lang=zh_cn&edition=full","pubTime":"2026-10-02 09:42","pubTimestamp":1790905379,"startTime":"0","endTime":"0","summary":"10月2日，科伦博泰生物盘中下跌3.45%，报461.6港元/股，成交额2835.3万港元。科伦博泰生物所在的生物科技行业中，板块整体承压，个股中，百济神州跌7.01%，信达生物跌4.9%，康方生物跌4.05%，三生制药跌5.73%，荣昌生物跌7.78%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175940364","title":"异动解读｜科伦博泰生物盘中上涨3.42%，芦康沙妥珠单抗多项研究入选ESMO大会LBA叠加板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1175940364","media":"行情直击","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175940364?lang=zh_cn&edition=full","pubTime":"2026-09-30 10:31","pubTimestamp":1790735513,"startTime":"0","endTime":"0","summary":"9月30日，科伦博泰生物盘中上涨3.42%，报489.2港元，成交额9263.27万港元。消息面上，公司近日公告自主研发的TROP2 ADC芦康沙妥珠单抗多项III期临床研究入选即将于10月举行的欧洲肿瘤内科学会（ESMO）大会最新突破性摘要（LBA），并将以口头报告形式呈现，构成近期核心催化。同时，生物科技板块今日整体走强，康希诺生物涨18.07%、百济神州涨2.75%、信达生物涨1.77%，板块共振效应延续。此外，东方证券于9月22日增持公司H股，好仓比例升至5.0%，机构资金持续关注。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰盘中上涨，ESMO大会LBA催化","news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671160812","title":"东方证券股份有限公司(DFZQ)增持科伦博泰生物(06990.HK)2.52万股 每股作价约490.76港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671160812","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671160812?lang=zh_cn&edition=full","pubTime":"2026-09-29 19:16","pubTimestamp":1790680598,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06990","03958","BK1161","LU0196878994.USD","BK1147","BK1564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181251520","title":"科伦博泰生物：东方证券增持，好仓比例升至5.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181251520","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181251520?lang=zh_cn&edition=full","pubTime":"2026-09-29 17:14","pubTimestamp":1790673264,"startTime":"0","endTime":"0","summary":"东方证券股份有限公司（DFZQ）于2026年9月22日在联交所场内以每股均价490.7615港元买入四川科伦博泰生物医药股份有限公司（科伦博泰生物，06990）H股2.52万股，涉资约1236.72万港元，属场内主动交易，即在二级市场直接买卖股份。东方证券此次增持前持有科伦博泰生物好仓881.94万股，占比4.98%；增持后持股量为884.46万股，好仓比例升至5.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671293354","title":"创新药概念股逆市走强 康方生物（09926）涨16.85%、康诺亚-B（02162）涨10.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671293354","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671293354?lang=zh_cn&edition=full","pubTime":"2026-09-29 13:20","pubTimestamp":1790659249,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股逆市走强，康方生物 涨16.85%，康诺亚-B涨10.32%，乐普生物涨7.88%，荣昌生物涨5.41%，科伦博泰生物涨5.32%，博安生物涨4.74%，恒瑞医药涨4.02%，再鼎医药涨4.02%。根据Insight数据，除已经在美国获批上市的药物外，已达成出海合作的国产创新药中有27款处于临床后期。其中，依沃西单抗、匹米替尼已在美国申请上市，芦康沙妥珠单抗、伦康依隆妥单抗、SSGJ-707等重点品种处于临床III期。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992749","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","09926","BK1191","LU0348825331.USD","LU0359201885.HKD","LNGR","LU0634319403.HKD","LU1961090484.USD","09688","LU0348827113.USD","LU2488822045.USD","IE00BPRC5H50.USD","LU0196878994.USD","06978","LU0359202008.SGD","LU0348766576.USD","LU0417516571.SGD","LU1969619763.USD","LU0348735423.USD","LU2328871848.SGD","MEDX","LU0561508036.HKD","06990","KURE","LU1023057109.AUD","LU2543165471.USD","LU1794554557.SGD","BK1587","LU2476274308.USD","LU2476274720.SGD","IE00B543WZ88.USD","LU2778985437.USD","IBBQ","LU0348767384.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0417516738.SGD","LU0359201612.USD","02162","LU1720050803.USD","09995","BK1161","06955","LU0348783233.USD","BK1574","BK1588","02157","159992","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118312838","title":"异动解读｜科伦博泰生物盘中上涨4.17%，芦康沙妥珠单抗多项研究入选ESMO大会LBA叠加板块共振","url":"https://stock-news.laohu8.com/highlight/detail?id=1118312838","media":"行情直击","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118312838?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:07","pubTimestamp":1790647640,"startTime":"0","endTime":"0","summary":"9月29日，科伦博泰生物盘中上涨4.17%，报474.2港元，成交额8935.05万港元。消息面上，公司近日公告自主研发的TROP2 ADC芦康沙妥珠单抗多项III期临床研究入选即将于10月举行的欧洲肿瘤内科学会大会最新突破性摘要，并将以口头报告形式呈现。同时，生物科技板块今日整体走强，康方生物涨12.17%、康诺亚-B涨7.66%，形成板块共振。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物上涨，芦康沙妥珠单抗入选ESMO大会LBA","news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669467248","title":"汇添富基金管理股份有限公司增持科伦博泰(06990.HK)2.52万股 每股作价约490.76港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669467248","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669467248?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:28","pubTimestamp":1790249303,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","LU0561508036.HKD","BK1576","LU0540923850.HKD","LU2399975544.HKD","LU3063872942.SGD","LU0348825331.USD","SG9999014674.SGD","09969","LU0348766576.USD","LU0348783233.USD","LU1242518931.SGD","LU1770034418.SGD","01548","LU0516423174.USD","02696","BK1515","688428","SG9999002463.SGD","LU0456846285.SGD","LU0516422366.SGD","LU0856984785.SGD","LU1961090484.USD","399441","LU0140636845.USD","02162","06160","BK1583","HK0000306701.USD","LU1880383366.USD","02269","09688","LU2039709279.SGD","LU2328871848.SGD","09995","LU1242518857.USD","BK1141","01877","161726","LU1303224171.USD","SG9999002562.SGD","LU0828237510.HKD","XBI","KURE","06990","09926","BK4581","LU1719994722.HKD","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669535961","title":"花旗：医药工业发展“十五五”规划利好创新药及医疗器械 首选石药集团(01093)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669535961","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669535961?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:03","pubTimestamp":1789974221,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，花旗发布研报称，工信部等部门联合发布《医药工业发展“十五五”规划》，核心是推动中国医药工业由规模驱动增长转向创新驱动、质量导向发展，并明确提出到2030年跻身世界领先行列的目标。规划涵盖创新药、创新医疗器械、人工智能驱动药物发现，以及CDMO/CRO等技术领域，显示政策正对整条价值链作出广泛支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MEDX","LU0456827905.SGD","SG9999002463.SGD","02269","BK4588","LU0516422366.SGD","LU3063872942.SGD","IYF","LU0561508036.HKD","LU1242518931.SGD","LU0516422440.USD","09996","01801","IE00B543WZ88.USD","LU1366192091.USD","159992","TFNS","FTXO","LGHT","BK1576","01093","06990","LU0455707207.USD","LU0067412154.USD","LU0029874905.USD","03347","BK4566","LU2417539215.USD","GDOC","LNGR","PTH","KURE","IBBQ","06978","MDEV","IEIH","LU0128525689.USD","HK0000165453.HKD","LU1807302812.USD","01276","LU0029874061.USD","159883","HART","LU1242518857.USD","LU0359201885.HKD","RSPH","LU1244550494.USD","AGNG","LU1226287875.USD","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":0.04},{"period":"1month","weight":0.0139},{"period":"3month","weight":-0.0948},{"period":"6month","weight":0.0073},{"period":"1year","weight":-0.0234},{"period":"ytd","weight":0.1933}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":-0.0357},{"period":"3month","weight":-0.0412},{"period":"6month","weight":-0.079},{"period":"1year","weight":-0.077},{"period":"ytd","weight":-0.0688}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品有抗体药物偶联物（ADC）SKB264和A166等。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等疾病的治疗。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.05939},{"month":2,"riseRate":0.666667,"avgChangeRate":0.239909},{"month":3,"riseRate":1,"avgChangeRate":0.292496},{"month":4,"riseRate":1,"avgChangeRate":0.083557},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.011152},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.022649},{"month":7,"riseRate":0.666667,"avgChangeRate":0.111158},{"month":8,"riseRate":1,"avgChangeRate":0.042518},{"month":9,"riseRate":0.75,"avgChangeRate":0.058448},{"month":10,"riseRate":0.25,"avgChangeRate":-0.035921},{"month":11,"riseRate":1,"avgChangeRate":0.072292},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"科伦博泰生物","nameEN":"SKB BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物,06990,科伦博泰生物股票,科伦博泰生物股票老虎,科伦博泰生物股票老虎国际,科伦博泰生物行情,科伦博泰生物股票行情,科伦博泰生物股价,科伦博泰生物股市,科伦博泰生物股票价格,科伦博泰生物股票交易,科伦博泰生物股票购买,科伦博泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}